Should LHRH therapy be continued in patients receiving abiraterone acetate? | Prostate Cancer and Prostatic Diseases

2022-08-26 19:55:33 By : Ms. Clare Feng

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prostate Cancer and Prostatic Diseases (2022 )Cite this article

Your institute does not have access to this article

Get full journal access for 1 year

All prices are NET prices. VAT will be added later in the checkout. Tax calculation will be finalised during checkout.

Get time limited or full article access on ReadCube.

All prices are NET prices.

The data used and/or analyzed are available from the corresponding author on request.

Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, et al. LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. Prostate Cancer Prostatic Dis. 2022. https://doi.org/10.1038/s41391-022-00533-6

Supiot S, Campion L, Pommier P, Dore M, Palpacuer C, Racadot S, et al. Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP. Oncotarget. 2018;9:22147–22157. https://doi.org/10.18632/oncotarget.25189

Article  PubMed  PubMed Central  Google Scholar 

Maluf FC, Schutz FA, Cronemberger EH, Luz MA, Martins SPS, Muniz DQB, et al. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur J Cancer. 2021;158:63–71. https://doi.org/10.1016/j.ejca.2021.08.032

CAS  Article  PubMed  Google Scholar 

Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, et al. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol. 2006;175:2072–7. https://doi.org/10.1016/S0022-5347(06)00273-4

CAS  Article  PubMed  Google Scholar 

Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363:1621–30. https://doi.org/10.1056/NEJMoa1001283

CAS  Article  PubMed  Google Scholar 

Department of Radiotherapy, ICO René Gauducheau, Boulevard du Professeur Jacques Monod, 44800, St-Herblain, France

Loic Ah-Thiane & Stéphane Supiot

CRCI2NA, Inserm UMR1232, CNRS ERL 6001, Nantes University, 44000, Nantes, France

You can also search for this author in PubMed  Google Scholar

You can also search for this author in PubMed  Google Scholar

The two authors contributed equally to this paper: LA: Writing—Original Draft, Writing—Review & Editing. SS: Conceptualization, Writing—Review & Editing.

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ah-Thiane, L., Supiot, S. Should LHRH therapy be continued in patients receiving abiraterone acetate?. Prostate Cancer Prostatic Dis (2022). https://doi.org/10.1038/s41391-022-00584-9

DOI: https://doi.org/10.1038/s41391-022-00584-9

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Prostate Cancer and Prostatic Diseases (Prostate Cancer Prostatic Dis) ISSN 1476-5608 (online) ISSN 1365-7852 (print)